HS
MRSN

HighVista Strategies’s Mersana Therapeutics MRSN Stock Holding History

HighVista Strategies’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,893
Closed -$548K – 150
2024
Q1 		$548K Buy
+4,893
New +$486K 0.2% 115
2021
Q3 		– Sell
-2,396
Closed -$814K – 135
2021
Q2 		$814K Buy
+2,396
New +$907K 0.58% 41

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's MRSN Position: Q2 2024 in Review

HighVista Strategies sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 4,893 shares — an estimated $548K sold.

HighVista Strategies first reported a position in MRSN in Q2 2021 and held it in 2 quarters. The position peaked at $814K in Q2 2021. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • HighVista Strategies reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HighVista Strategies sold 4,893 Mersana Therapeutics shares in Q2 2024, an estimated $548K.
  • HighVista Strategies first reported a position in Mersana Therapeutics in Q2 2021 and held it in 2 quarters.
  • HighVista Strategies's Mersana Therapeutics position peaked at $814K in Q2 2021.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.